Clinical Efficacy of L-ornithine-L-aspartate in the Management of Icteric Chronic Viral Hepatitis

王宇明,张绪清,王小红,马巧玉,陈嵩,李玲,陈耀凯,蒋黎

DOI: https://doi.org/10.3969/j.issn.1001-9057.2007.04.013

2007-01-01

Abstract:Objective Aim To evaluate clinical efficacy of L-ornithine-L-aspartate in the management of icteric chronic viral hepatitis.Methods 108 patients with icteric chronic viral hepatitis were randomly divided into three groups,who received 4 weeks treatment with intravenous L-ornithine-L-aspartate,S-adenosyl-L-methionine,potassium magnesium aspartate,respectively.The serum total bilirubin was tested in all patients at the onset and the end of treatment.Results The effective rates of lowering serum total bilirubin were 75.0% and 72.5% respectively in the group with L-ornithine-L-aspartate and S-adenosyl-L-methionine,which were significantly higher than that in the group with potassium magnesium aspartate(30.6%),P0.01.The daily levels of decreased serum total bilirubin were 4.3±5.1μmol/L and 4.3±5.6μmol/L respectively in the group with L-ornithine-L-aspartate and S-adenosyl-L-methionine, which were significantly higher than that in the group with potassium magnesium aspartate(2.1±8.3μmol/L),P0.01.Conclusion The levels of serum total bilirubin are effectively decreased in the patients with icteric chronic viral hepatitis by the management of intravenous L-ornithine-L-aspartate.